Improving cefazolin exposure in critically ill children using a population pharmacokinetic model
Use of individualized cefazolin model-informed dosing improves critically ill children's exposure. Further studies are needed to assess the clinical benefit of cefazolin PK model application.
Authors
- Sylvain Renolleau (ORCID: https://orcid.org/0000-0002-0638-5613)
- Julie Toubiana (ORCID: https://orcid.org/0000-0001-9561-669X)
- Sihem Benaboud
- Déborah Hirt (ORCID: https://orcid.org/0000-0002-9898-2609)
- Delphine Callot (ORCID: https://orcid.org/0000-0003-3695-575X)
- Noémie de Cacqueray (ORCID: https://orcid.org/0009-0002-4280-4683)
- Mehdi Oualha (ORCID: https://orcid.org/0000-0002-0488-5948)
- Agathe Béranger (ORCID: https://orcid.org/0000-0002-9751-8249)
- Steeve Rouillon
- Jean‐Marc Tréluyer (ORCID: https://orcid.org/0000-0002-2045-4742)
- Léo Froelicher Bournaud (ORCID: https://orcid.org/0009-0001-3950-7728)
- Clémence Rivaud
- Elodie Salvador
- Emmanuelle Bille (ORCID: https://orcid.org/0000-0001-9172-0510)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Necker Enfants Malades (FR)
- Hôpital Cochin (FR)
- HiFiBiO Therapeutics (France) (FR)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1111/bcp.16224
- Citations
- 2
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.90